Identification of an Additional P53-responsive Site in the Human Epidermal Growth Factor Receptor Gene Promotor
Overview
Affiliations
Exogenously introduced wild-type and mutant p53 have recently been reported to enhance the human epidermal growth factor receptor (EGF-R) gene promoter activity in p53-deficient Saos2 osteosarcoma cells. A p53 binding site residing at position -265/-239 in the EGF-R proximal promoter has also been identified. We investigated the p53 regulation of EGF-R core promoter activity in human cell lines with varying endogenour p53 status. Wild-type and mutant p53Ala143 enhanced the EGF-R core promotor activity in cells that were either p53-deficient or contained wild-type or mutant endogenous p53. Upon further characterization of the various deletion fragments of the EGF-R promoter, we identified a wild-type p53 responsive 62 bp region residing at position -167/-105. The -167/-105 segment was responsive only to wild-type p53 but not to mutant p53Ala143 or p53His273. The -167/-105 segment of the EGF-R promotor contains one perfect and several imperfect consensus p53-binding half sites; indeed in gel shift experiments the 62 bp -167/-105 segment as well as the oligonucleotides corresponding to two p53 consensus half-sites within the 62 bp fragment, exhibited binding to p53-containing protein complexes. Thus, we have identified an additional wild-type p53 responsive site in the human EGF-R promoter. This site containing consensus p53-binding sequences resides at position -167/-105 and is proximal to recently identified p53 binding element located at position -265/-239 in the EGF-R promotor.
Erichsen L, Thimm C, Wruck W, Kaierle D, Schless M, Huthmann L Int J Mol Sci. 2023; 24(9).
PMID: 37175937 PMC: 10179415. DOI: 10.3390/ijms24098228.
RNF128 Promotes Malignant Behaviors via EGFR/MEK/ERK Pathway in Hepatocellular Carcinoma.
Bai X, Zhang C, Peng R, Jiang G, Jin S, Wang Q Onco Targets Ther. 2020; 13:10129-10141.
PMID: 33116595 PMC: 7553654. DOI: 10.2147/OTT.S269606.
Gao J, Wang Y, Yang J, Zhang W, Meng K, Sun Y Cancers (Basel). 2019; 11(6).
PMID: 31216681 PMC: 6627419. DOI: 10.3390/cancers11060840.
Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer.
de Almeida V, Melo A, Meira D, Pires A, Nogueira-Rodrigues A, Pimenta-Inada H Braz J Med Biol Res. 2017; 51(1):e6822.
PMID: 29160417 PMC: 5685065. DOI: 10.1590/1414-431X20176822.
Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model".
Purba E, Saita E, Maruyama I Cells. 2017; 6(2).
PMID: 28574446 PMC: 5492017. DOI: 10.3390/cells6020013.